Michael D. Spera

Associate

spera-michael
  • JD, Northeastern University School of Law, 2013
  • BA (Political Science), magna cum laude, Tufts University, 2010

Qualifications

  • Massachusetts, 2013
  • Lifestars “European Deal of the Year Under £500 Million” (2019)

Michael D. Spera

Associate

Michael’s practice focuses on mergers and acquisitions, divestitures, joint ventures and other complex strategic partnerships for both public and private companies, primarily in the pharmaceutical, biotechnology and medical device industries. Michael also regularly counsels clients on a range of corporate governance and commercial matters.

During law school, Michael served as a judicial intern for the Honorable Norman H. Stahl of the U.S. Court of Appeals for the First Circuit. Michael also served as a law clerk in the legal department of Rady Children’s Hospital – San Diego.

Experience

  • Represented Vertex Pharmaceuticals in its acquisition of Exonics Therapeutics for $245 million plus contingent consideration.
  • Represented a leading global pharmaceutical company in its divestiture of global rights to its product intended for the treatment of idiopathic multicentric Castleman’s disease.
  • Represented a leading global pharmaceutical company in its acquisition of clinical stage assets intended for the treatment of spinal muscular atrophy.
  • Represented a leading global pharmaceutical company in its divestiture of its U.S. and Canadian rights to its pancreatic enzyme replacement product.
  • Represented a leading global medical device company in its acquisition and license of assets for use in the development and commercialization of its existing knee implant offerings.
  • Represented a leading global pharmaceutical company in a series of divestitures of its Canadian and Japanese rights to a pain management drug franchise.
  • Represented a leading global medical device company in its divestiture of its vertebral augmentation business. 
  • Represented a leading global medical device company in its acquisition of a novel technology for the treatment of Meibomian Gland Dysfunction, a primary cause of dry eye disease.
  • Represented a leading global pharmaceutical company in a series of FDA-issued priority review voucher acquisitions. 
  • Represented Symmetry Surgical, a leading provider of surgical instrumentation and specialty devices, in its take-private acquisition by RoundTable Healthcare Partners.
  • Represented a leading global pharmaceutical company in a co-promotion arrangement.
  • JD, Northeastern University School of Law, 2013
  • BA (Political Science), magna cum laude, Tufts University, 2010
Cookie Settings